Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
BACKGROUND
We aimed to compare the effect of unfractionated heparin (UFH) and enoxaparin used as anticoagulants during hemodialysis (HD) on circulating levels of heparin-binding, endothelial-derived, proangiogenic factors-vascular endothelial (VEGF(165)) and basic fibroblast (bFGF) growth factor.


METHODS
We enrolled 22 chronic HD patients, who were randomly assigned to either enoxaparin (n=11) or UFH (n=11) anticoagulation, and followed prospectively for 12 weeks before crossing over to the alternate therapy for further 12 weeks. The cytokines were measured by immunoassay at the start, at 10 and 180min of HD.


RESULTS
The baseline VEGF(165) and bFGF levels were comparable during enoxaparin and UFH treatment. VEGF(165) significantly decreased during both enoxaparin (chi(2) ANOVA=33.0, P<10(-6)) and UFH (chi(2) ANOVA=27.2, P<10(-6)) anticoagulated HD, while over-HD bFGF remained stable regardless of the type of heparin. The switch from enoxaparin to UFH treatment was connected with 34% VEGF(165) decrease after 180min of HD and had no impact on bFGF. During UFH-anticoagulated HD 75% VEGF(165) decrease after 10min was negatively associated with heparin dosage and was more profound in patients with ischemic heart disease.


CONCLUSIONS
The traditional UFH regimen, in contrast to enoxaparin treatment, is connected with dose-depended VEGF(165) decrease during HD procedure. The biological and possible clinical relevance of this observation requires further investigations.
Naumnik
Beata
B
Department of Nephrology and Transplantation with Dialysis Unit, Medical University, 14 Zurawia Street, 15-540 Białystok, Poland. bnaumnik@poczta.onet.pl
Pawlak
Krystyna
K
Myśliwiec
Michał
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004730:Endothelium, Vascular / Q000378:metabolism; D017984:Enoxaparin / Q000008:administration & dosage*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000628:therapy; D006435:Renal Dialysis; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D000925:Anticoagulants; D017984:Enoxaparin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D006493:Heparin